HHS, DOD award $481M for point-of-care COVID-19 test, announce vaccine manufacturer partnership
The Department of Health and Human Services and the Department of Defense yesterday awarded $481 million to Cue Health Inc. to expand production of a point-of-care COVID-19 molecular test with capabilities to produce results in 20 minutes.
Cue said the highly sensitive test uses a nasal swab sample to detect RNA of SARS-CoV-2, the virus that causes COVID-19. HHS said the partnership allows Cue to increase production to 100,000 test kits per day by March 2021.
Also yesterday, HHS and DOD announced a separate, $31 million agreement with Cytiva to expand the company’s capacity to produce items essential to the production of COVID-19 vaccines such as liquid and dry powder cell culture media, cell culture buffers, mixer bags, and bioreactors.
Related News Articles
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…